Noninferiority (NI) phase III trials in oncology: What is the basis for choosing the NI margin?

被引：0
|
作者：
Militao, M. S. [1 ]
Saad, E. D. [1 ]
机构：
[1] Dendrix Res, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e13070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13070
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?
    Suji Udayakumar
    Sasha Thomson
    Albiruni R. Abdul Razak
    Kelvin K. W. Chan
    Targeted Oncology, 2022, 17 : 665 - 674
  • [32] An analysis of phase II biologic studies and subsequent phase III trials - What are the predictors
    Ueda, Stefanie M.
    Sugiyama, Valerie E.
    Shin, Jacob Y.
    Kapp, Daniel S.
    Osann, Kathryn
    Chan, John K.
    OBSTETRICS AND GYNECOLOGY, 2007, 109 (04): : 121S - 122S
  • [33] Predicting low accrual in the Clinical Trials Cooperative Group Program's phase II/III oncology trials
    Bennette, Caroline Savage
    Ramsey, Scott David
    McDermott, Cara L.
    Carlson, Josh John
    Basu, Anirban
    Veenstra, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Stakeholder perspectives on the use of positron emission tomography in phase III oncology trials in the UK
    Rojas-Anaya, Hector
    Skogen, Karoline
    Miles, Kenneth Alan
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (06) : 626 - 632
  • [35] Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.
    Rahman, Rifaquat
    Fell, Geoffrey
    Trippa, Lorenzo
    Alexander, Brian Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Processes to activate phase III clinical trials in a cooperative oncology group: The elephant is monstrous
    Steensma, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1148 - 1148
  • [37] Independent central review of progression in randomized phase II/III oncology trials: Is it needed?
    Wu, W.
    Lin, L. I.
    Sargent, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Evaluation and Enhancement of the Informed Consent Process in Phase III Pediatric Oncology Clinical Trials
    Sedig, Laura
    Hutchinson, Raymond
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S60 - S61
  • [39] Poor quality of adverse event reporting in oncology phase III trials: A systematic review
    Maillet, D.
    You, B.
    Peron, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S193 - S194
  • [40] A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice
    Tam, V. C.
    Tannock, I.
    Rauw, J.
    Krzyzanowska, M. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345